
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is a promising investment opportunity with the potential to revolutionize CAR-T therapy and enter new markets due to its EB103 technology platform. This platform addresses limitations of current CD19 CAR-T therapies and has shown promising data in Phase I trials. The company's entry into Phase II trials and expected generation of additional clinical data further strengthens its potential success and adds to its valuation as a sound investment opportunity.
Bears say
Estrella Immunopharma is facing multiple risks including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks, which could negatively impact their milestone and royalty revenue. Their recent capital raise may support their short-term clinical execution, but their declining stock price raises concerns about future dilution and signals potential updates on partnering and pipeline prioritization. As a financial analyst, a recommended conservative stance would be to lower the target price for the stock from $16.0 to $8.0.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares